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Urine soluble triggering receptor expressed on
myeloid cells-1 (sTREM-1) has been reported in sepsis
diagnosis and prediction of sepsis-associated acute
kidney injury (AKI). However, the mechanisms of the
role of sTREM-1 for AKI remain unclear. It may be that
topical inflammatory response of kidney, not just
systemic inflammation, contributes to the elevated
secretion of urine sTREM-1 in the process of sepsis-
associated AKI. To further evaluate the role of sTREM-1
in this process, a larger-cohort multicenter study and
the relevant basic research should be performed to
reveal the diagnostic value and mechanism of sTREM-1
during the sepsis-associated AKI process. If successful,
then urine sTREM-1 would be a good marker for sepsis
and its associated AKI and could contribute to non-
invasive diagnosis and monitoring in the clinical setting.
Additionally, owing to the complexity of the
pathogenesis of sepsis, it is necessary to combine some
biomarkers to improve diagnostic performance in the
diagnosis of sepsis-associated AKI rather than relying on
a single marker.disease progresses or AKI appears, urine sTREM-1 ele-
vated rapidly, suggesting poor prognosis. Secondly, urineAlthough the diagnostic and predictive values of plasma
and urine neutrophil gelatinase-associated lipocalin (NGAL)
and cystatin-C (Cys-C) for sepsis-associated acute kidney
injury (AKI) are generally accepted as reliable [1, 2], the
diagnostic value of urine soluble triggering receptor
expressed on myeloid cells-1 (sTREM-1) is attracting
more attention. In a recent article in Critical Care, Dai* Correspondence: dwliu98@163.com
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creativecommons.org/publicdomain/zero/1.0/and colleagues [3] successfully collected plasma and urine
and measured NGAL, Cys-C, and sTREM-1 and reported
that both plasma and urine NGAL, Cys-C, and sTREM-1
levels were significantly increased at the time of diagnosis
and 24 hours before AKI diagnosis. They once again
proved urine sTREM-1 for sepsis-associated AKI diagno-
sis and confirmed the conclusion that was published by us
in Critical Care in 2011 [4].
TREM-1 is a member of the immunoglobulin super-
family of receptors which is expressed on polymorpho-
nuclear granulocytes and mature monocytes. It has been
acknowledged that the levels of sTREM-1 in body fluid
samples increased at the occurrence of infectious dis-
eases, such as sepsis, pneumonia, septic arthritis, menin-
gitis, peritonitis, and uterine cavity infection [5]. It was
also reported that serum sTREM-1 could be used in the
assessment of severity or even prognosis of sepsis [6, 7].
The advantages of sTREM-1 for the diagnosis of
sepsis-associated AKI are the following: Firstly, the con-
centration of urine sTREM-1 stays high in sepsis; that is,
the sTREM-1 concentration in the urine of patients with
sepsis is 30 to 50 pg/ml, whereas the concentration of
sTREM-1 in normal urine is almost undetectable. As the
sTREM-1 has great value for the early diagnosis of AKI,
especially 24 and 48 hours prior to the AKI occurrence.
The area under a receiver operating characteristic curve
of urine sTREM-1 for AKI diagnosis was 0.7 to 0.9.
Thirdly, dynamic change in the urine sTREM-1 also sug-
gests the possibility of the AKI occurrence; that is, an in-
creasing trend of sTREM-1 may predict the risk of AKI
or even poor prognosis. Fourthly, it has been demon-
strated that urine sTREM-1 is the risk factor for AKI oc-
currence in septic patients according to multivariate
analysis logistic regression.distributed under the terms of the Creative Commons Attribution License
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ment in diagnosing sepsis-related AKI, Derive and Gibot
[8] raised a question: where does urinary sTREM-1 ori-
ginate from? The alteration of both plasma and urine
sTREM-1 concentration in the non-AKI patient with
sepsis was mild but was very dramatic in the case of AKI.
From both the plasma and urine concentrations of
sTREM-1 during AKI, we think that secretion of sTREM-
1 in plasma and urine may not be parallel. This paradox-
ical manifestation indicates that the topical inflammatory
response of kidney could be involved in the AKI process,
not just the systemic inflammatory response. Thus,
sTREM-1 may be produced locally by the endothelial cells,
tubular epithelial cells, or infiltrating inflammatory cells
that are recruited during acute tubular necrosis. Conse-
quently, sTREM-1 may be released into the blood circula-
tion as a result of alteration in glomerular filtration barrier
membrane pore size and charge. These possible mecha-
nisms are summarized and illustrated in Fig. 1. Therefore,
animal or cell experiments (or both) are necessary to con-
firm whether the use of TREM-1 inhibitors could block
the process of sepsis-associated renal local inflammatory
immune status.
The increasingly successful example of the research of
urinary biomarkers provides the opportunity for non-
invasive detection and continuous monitoring of sepsis
patients in the intensive care unit. It has been reported
that sTREM-1 represented reliable diagnostic value for
sepsis through meta-analysis [9, 10]. Of particular note,
sTREM-1 could be secreted to and detected from urineFig. 1 Schematic illustration of the possible mechanisms of urine sTREM-1
receptor, TLR Toll-like receptor, sTREM-1 soluble triggering receptor expresseduring sepsis and its associated AKI; thus, we predict
that urine sTREM-1 will be used for non-invasive and
continuous monitoring for sepsis and its associated AKI.
However, a large sample size and multicenter study are
necessary to validate this potential biomarker. In this re-
gard, since December 2012, a larger-cohort multicenter
study joined by dozens of larger hospitals in the North
of China has been in progress. From this large study, we
expect the following: (1) the diagnostic value of urine
sTREM-1 in sepsis and its associated AKI, especially for
early diagnosis, will be confirmed; (2) the prognostic
value of sTREM-1 in sepsis and its associated AKI will
be assessed; (3) the correlation between sTREM-1 and
classification of AKI proposed by Kidney Disease: Im-
proving Global Outcomes (KDIGO) or the relationship
between Acute Physiology and Chronic Health Evalu-
ation II (APACHE II) and Sequential Organ Failure As-
sessment (SOFA) score will be evaluated; and (4) the
influence of renal replacement therapy on the produc-
tion and secretion of sTREM-1 will also be evaluated.
Each biomarker has its advantages and disadvantages.
In some cases, it may be inappropriate to use certain
biomarkers. For example, pre-existing kidney disease may
interfere with the NGAL concentration by reabsorption
through megalin-dependent endocytosis [11]. Septic pa-
tients with underlying diseases, such as cancer, or chronic
kidney disease patients who are undergoing renal replace-
ment therapy, or who are immunosuppressed or undergo-
ing steroid treatment, may have false-negative results
when these biomarkers are detected [12–14]. There seemssecretion in sepsis-associated AKI. AKI acute kidney injury, NLR Nod-like
d on myeloid cells-1
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diagnosis. Therefore, a combination of biomarkers might
be more valuable and precise in diagnosing sepsis-
associated AKI. And it may be useful to develop a panel of
biomarkers to improve the diagnostic efficacy of AKI.
That is, some biomarkers—for example, combined NGAL,
Cys-C, sTREM-1, or other biomarkers—should be taken
together in diagnosing and assessing the prognosis of AKI.
This could make it possible to increase the sensitivity and
specificity of the diagnostic efficacy of AKI.
Urine sTREM-1 may become a non-invasive diagnostic
and prognostic marker for sepsis and its associated AKI.
Combined multiple biomarkers and their respective ad-
vantages may improve the diagnostic performance of
sepsis and its associated AKI. A larger-cohort multicen-
ter study and relevant basic research should be carried
out to reveal its clinical significance and molecular
mechanism.
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